Maximizing the health of women with epilepsy: Science and ethics in new drug development

Epilepsia

Volumn 38, Issue SUPPL. 4, 1997, Pages

  Morrell, Martha J ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticonvulsant drugs; Clinical drug evaluation; Clinical trials; Drug therapy; Drug toxicity; Epilepsy; Fertility; Hormones; Reproduction; Teratogens; Women

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG TOLERABILITY; EPILEPSY; FAMILY PLANNING; FEMALE; HORMONE ACTION; HUMAN; LACTATION; MEDICAL ETHICS; ORAL CONTRACEPTION; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; SEXUALITY; TERATOGENESIS;

EID: 0030835690     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb04537.x     Document Type: Article

References (119)

1. Morrell MJ. Hormones, reproductive health and epilepsy. In: Wyllie E, Ed. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore: Williams & Wilkins, 1997.
2. Pfaff DW and Keiner M. Atlas of estradiol-concentrating cells in the central nervous system of the female rat. J Comp Neurol 1973;151:121-58.
3. A-receptor modulation. Brain Res 1993;615:267-74.
4. A-benzodiazepine receptor. Eur J Pharmacol 1990;188: 403-6.
5. Morrow L, Pace JR, Purdy RH, Paul SM. Characterization of steroid interactions with gamma-aminobutyric acid receptor-gated chloride ion channels: evidence for multiple steroid recognition sites. Mol Pharmacol 1989;37:263-70.
6. A receptor subunits. Neuroscience 1993;19:1191.
7. Weiland NG, Orchinik M, Brooks PJ, McEwen BS. Allopregnanolone mimics the action of progesterone on glutamate decarboxylase gene expression in the hippocampus. Neuroscience 1993;19:1191.
8. McCarthy MM, Kaufman LC, Brooks PJ, Pfaff DW. Estrogen modulation of mRNA for two forms of glutamic acid decarboxylase (GAD) in rat brain. Neuroscience 1993;19:1191.
9. Weiland NG. Glutamic acid decarboxylase messenger ribonucleic acid is regulated by estradiol and progesterone in the hippocampus. Endocrinology 1992;131:2697-702.
10. Wallis CJ, Luttge WG. Influence of estrogen and progesterone on glutamic acid decarboxylase activity in discrete regions of rat brain. J Neurochemistry 1980;34:609-13.
11. Weiland NG. Estradiol selectively regulates agonist binding sites on the N-methyl-D-aspartate receptor complex in the CA-1 region of the hippocampus. Endocrinology 1992;131:662-8.
12. Smith SS, Waterhouse BD, Chapin JK, Woodward DJ. Progesterone alters GABA and glutamate responsiveness: a possible mechanism for its anxiolytic action. Brain Res 1987;400:353-9.
13. Finn DA, Gee KW. The estrous cycle, sensitivity to convulsants and the anticonvulsant effect of a neuroactive steroid. J Pharmacol Exp Ther 1994;271:164-70.
14. Finn DA, Ostrom R, Gee KW. Estrous cycle and sensitivity to convulsants and the anticonvulsant effect of 3α-Hydroxy-5α-pregnan-20-one(3α,5α-P). Neuroscience 1993;19:1539.
15. Finn DA, Gee KW. The influence of estrous cycle on neurosteroid potency at the gamma-aminobutyric acid. J Pharmacol Exp Ther 1993;265:1374-9.
16. Morrell MJ. Hormones and epilepsy through the lifetime. Epilepsia 1992;33(suppl 4):S49-61.
17. Dana-Haeri J, Trimble MR, Oxley J. Prolactin and gonadotrophin changes following generalized and partial seizures. J Neurol Neurosurg Psychiatry 1983;46:331-5.
18. Sperling MR, Pritchard PB, Engel J, Daniel C, Sagel J. Prolactin in partial epilepsy: an indicator of limbic seizures. Ann Neurol 1986;20:716-22.
19. Pritchard PB. The effect of seizures on hormones. Epilepsia 1991; 32(suppl 6):S46-50.
20. Dana-Haeri J, Oxley J, Richens A. Pituitary responsiveness to gonadotrophin-releasing and thyrotrophin-releasing hormones in epileptic patients receiving carbamazepine or phenytoin. Clin Endocrinol 1984;20:163-8.
21. Drislane FW, Coleman AE, Schomer DL, et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology 1994;44:306-10.
22. Meo R, Bilo L, Nappi C, Tommaselli AP, et al. Derangement of the hypothalamic GnRH pulse generator in women with epilepsy. Seizure 1993;2:241-252.
23. Isojarvi JIT, Parakinen AJ, Rautio A, Pelkoren O, My Uyla W. Serum sex hormone levels after replacing carbamazepine with oxcarbazepinc. Eur Clin Pharmacol 1995;47:461-4.
24. Macphee GJ, Larkin JG, Butler E, Beatsall GH, Brodie MJ. Circulating hormones and pituitary responsiveness in young epileptic men receiving long-term antiepileptic medication. Epilepsia 1988;29:468-75.
25. Franceschi M, Perego L, Cavagnini F, et al. Effects of long-term antiepileptic therapy in the hypothalamic-pituitary axis in man. Epilepsia 1984;25:46-52.
26. Luhdorf K. Endocrine function and antiepileptic treatment. Acta Neurol Scand 1983;67(suppl 94):15-19.
27. Levesque LA, Herzog AG, Seibel MM. The effect of phenytoin and carbamazepine on serum dehydroepiandrosterone sultate in men and women who have partial seizures with temporal lobe involvement. J Clin Endocrinol Metab 1986;63:243-5.
28. Dana-Haeri J, Oxley J. Reduction of free testosterone by antiepileptic drugs. BMJ 1982;284:85-6.
29. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KTS, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
30. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986;256:238-40.
31. Haukkamaa M, Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 1986;33:559-65.
32. Morrell MJ. Use of the new antiepileptic drugs in women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia 1997 (in press).
33. Schupf N, Ottman R. Likelihood of pregnancy in individuals with idiopathic/cryptogenic epilepsy: social and biologic influence. Epilepsia 1994;35:750-6.
34. Webber MP, Hauser WA, Ottman R, Annegers JF. Fertility in persons with epilepsy: 1935-1974. Epilepsia 1986;27:746-52.
35. Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980;21:261-71.
36. Bilo L, Meo R, Valentino R, Buscaino GA, Straino S, Nappi C. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril 1991;55:705-11.
37. Herzog AG, Seibel MM, Schomer D, Vaitukaitas J, Geschwind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome. Neurology 1984;34:1389-93.
38. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-6.
39. Cummings LN, Giudice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia 1995;36:355-9.
40. Polson DW, Wadsworth J, Adams J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet 1988:870-72.
41. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust NZJ Obstet Gynecol 1994;34:1-67.
42. Clayton RN, Ogden V, Hodgkinson J, et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol 1992;37:127-34.
43. Philbert A, Dam M. The epileptic mother and her child. Epilepsia 1982;23:85-99.
44. Yerby MS, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 1985; 26:631-5.
45. Steegers-Theunissen RPM, Renier WO, Borm GF, et al. Factors influencing the risk of abnormal pregnancy outcome in epileptic women: a multicentre prospective study. Epilepsy Res 1994;18: 261-9.
46. Morrell MJ. Sexuality in epilepsy. In: Engel J, Pedley TA, eds. Epilepsy: a comprehensive textbook. New York: Lippincott-Raven, 1997 (in press).
47. Taylor DC. Sexual behavior and temporal lobe epilepsy. Arch Neurol 1969;21:510-16.
48. Blumer D, Walker AE. Sexual behavior in temporal lobe epilepsy. Arch Neurol 1967;16:37-43.
49. Hierons R, Saunders M. Impotence in patient with temporal lobe lesions. Lancet 1966;2:761-4.
50. Demerdash A, Shaalon M, Midori A, Kamel F, Bahri M. Sexual behavior of a sample of females with epilepsy. Epilepsia 1991; 32:82-5.
51. Jensen P, Jensen SB, Sorensen PS, et al. Sexual dysfunction in male and female patients with epilepsy: a study of 86 outpatients. Arch Sex Behav 1990;19:1-14.
52. Fenwick PBC, Toone BK, Wheeler MJ, Nanjee MN, Grant R, Brown D. Sexual behavior in a centre for epilepsy. Acta Neurol Scand 1985;71:428-35.
53. Pritchard PB. Hyposexuality: a complication of complex partial epilepsy. Trans Am Neurol Assoc 1980;105:193-5.
54. Morrell MJ, Guldner GT. Self-reported sexual function in women with epilepsy. Epilepsia 1994;35:108.
55. Guldner GT, Morrell MJ. Nocturnal penile tumescence and rigidity evaluation in men with epilepsy. Epilepsia 1996;37:1211-14.
56. Fenwick PBC, Mercer C, Grant R, et al. Nocturnal penile tumescence and serum testosterone levels. Arch Sex Behav 1986;15: 13-21.
57. Morrell MJ, Sperling MR, Stecker M, Dichter MA. Sexual dysfunction in partial epilepsy: a deficit in physiological sexual arousal. Neurology 1994;44:243-7.
58. Morrell MJ. Sexual dysfunction in epilepsy. Epilepsia 1991;32 (suppl 5):S38-45.
59. Kaplan HS. The evaluation of sexual disorders: psychological and medical aspects. New York: Brunner/Mazel, 1983.
60. The Medical Letter. Intracavernous injection of alprostadil for erectile dysfunction. 1995;37:83-4.
61. Valimaki M, Tiihonen, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patient on antiepileptic drugs. J Bone Min Res 1994;9:631-7.
62. Sheth R, Wesolowski C, Jacob J, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-62.
63. Chung S, Ahn C. Effects of antiepileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Develop 1994;16:382-5.
64. Bogliun G, Beghi E, Crespi V, Delodovick L, d'Amico P. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986; 74:284-8.
65. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on Vitamin D and calcium metabolism in out-patients with epilepsy. QJM 1986; 230:569-77.
66. Marcus R. Secondary forms of osteoporosis. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:889-904.
67. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharacol Ter 1987;33:139-44.
68. Schmidt D, Beck-Mannagetta G, Janz D, Koch S. The effect of pregnancy on the course of epilepsy: a prospective study. In: Janz D, et al., eds. Epilepsy, pregnancy and the child. New York: Raven Press, 1982:39-49.
69. Yerby MS, Friel PN, McCormick KB, et al. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res 1990;5:223-8.
70. Morrell MJ. Pregnancy and Epilepsy. In: Porter RJ, Chadwick D, eds. The epilepsies II. Boston: Butterworth, 1996 (in press).
71. Gaily E, Granstrom M-L. Minor anomalies in children of mothers with epilepsy. Neurology 1992;42(suppl 5): 128-31.
72. Friis ML. Facial clefts and congenital heart defects in children of parents with epilepsy: genetic and environmental etiologic factors. Acta Neurol Scand 1989;79:433-59.
73. Annegers JF, Hauser WA, Elveback LR, et al. Congenital malformations and seizure disorders in the offspring of parents with epilepsy. Int J Epidemiol 1978;7:241-7.
74. Omtzigt JGC, Los FJ, Grobee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):119-25.
75. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-7.
76. Gaily E, Kantola-Sorsa E, Granstrom ML. Intelligence of children of epileptic mothers. J Pediatr 1988;113:677-84.
77. Koch S, Loesche G, Jager-Roman E, et al. Major birth malformations and antiepileptic drugs. Neurology 1992;42(suppl 5): 83-8.
78. Granstrom M-L, Gaily E. Psychomotor development in children of mothers with epilepsy. Neurology 1992;42(suppl 5):144-8.
79. Battino D, Granata T, Binelli S, et al. Intrauterine growth in the offspring of epileptic mothers. Acta Neurol Scand 1992;86: 555-7.
80. Hiilesmaa et al. Fetal head growth retardation associated with maternal antiepileptic drugs. Lancet 1981;2:165-7.
81. Yerby MS. Pregnancy and epilepsy. Epilepsia 1991;32:S51-59.
82. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepilepsy drugs: analysis of possible risk factors. Epilepsia 1988; 29:459-67.
83. Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991;8:75-8.
84. Sander JWAS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res 1992;13:89-92.
85. Dansky L, Andermann E, Roseblatt D, et al. Anticonvulsants, folate levels and pregnancy outcome. Ann Neurol 1987;21:176-82.
86. Mulinare J, Corder JF, Erickson JD, et al. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-5.
87. Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1988;262:2847-52.
88. Werler MM. Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993; 269:1257-61.
89. Laurence KM, James N, Miller MH, et al. Double-blind, randomized controlled trial of folate treatment before conception to prevent the recurrence of neural-tube defects. BMJ 1981;282:1509-11.
90. Medical Research Council Vitamin Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
91. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-5.
92. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural tube defects. Lancet 1995;345:149-51.
93. Van Allen M, Fraser FC, Dallaire L, et al. Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Can Med Assoc J 1993;149:1239-43.
94. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep 1992;41:1-7.
95. Buehler BA, Delimont D, Van Waes M, Finnell RH. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990;322:1567-72.
96. Finnel RH, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992;42:25-31.
97. Strickler SM, Miller MA, Andermann E, et al. Genetic predisposition to phenytoin-induced birth defects. Lancet 1985;2:746-9.
98. Oguni M, Dansky L, Andermann E, et al. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev 1992;14:371-80.
99. Commission on Genetics, Pregnancy, and the Child, International League Against Epilepsy. Guidelines for the care of women of childbearing age with epilepsy. Epilepsia 1993;34:588-9.
100. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992;42(suppl 5): 149-60.
101. FDA. Use-in-pregnancy drug categories. 21 CFR§201.57 (f)(6) (i)(a)-(e).
102. FDA. General considerations for the clinical evaluation of drugs. Washington, DC: Government Printing Office, 1977 [Publication No: HEW(FDA)77-3040].
103. Merkatz RB, Temple R, Sobel S, et al. Women in clinical trials of new drugs: a change in Food and Drug Administration Policy. N Engl J Med 1993;329:292-6.
104. NIH/ADAMHA. Policy concerning the inclusion of women in study populations. NIH guide for grants and contracts, 1990.
105. NIH. NIH Revitalization Act. 1993. Public Law (Pub.L.) 103-43.
106. NIH. NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register 1994;59:14508-13.
107. FDA/DHHS. Guidelines for the study of and evaluation of gender differences in the clinical evaluation of drugs. Federal Register 1993;58:39406-16.
108. Morrell MJ. Issues for women in antiepileptic drug development. In: Dichter MA, French JA, Leppik I, eds. Antiepileptic drug trials III. New York: Lippincott-Raven, 1997 (in press).
109. Garofalo E, Eardley D, Koto E, LaMoreaux L. The effectiveness of gabapentin (neurontin) stratified by gender. Epilepsia 1994;35 (suppl 7):69.
110. Pledger G, Reife R, Lim P, Karim R. Overview of topiramate efficacy from adjunctive therapy trials. Epilepsia 1995;36(suppl 3):S150.
111. DHHS. Additional DHHS protections pertaining to research, development, and related activities involving fetuses, pregnant women, and human in vitro fertilization. Title 45. Code of Federal Regulations. Part 46, sub part B; March 15, 1994.
112. NIH/Office for Protection from Research Risks (OPRR). Protection for human subjects. 1991;45:CFR 46.
113. Institute of Medicine. Women and health research: ethical and legal issues of including women in clinical studies. Washington, DC: National Academy Press, 1994:1-25.
114. Annas G. Fetal protection and employment discrimination - the Johnson Controls Case. N Engl J Med 1991;325:740-3.
115. Civil Rights Act of 1964 (as amended), 42 USC section 2000d, et seq.
116. Pregnancy Discrimination Act of 1978.92 Stat. 2076, 42 U.S.C. Sec 2000e (k).
117. FDA/DHHS. International Conference on Harmonization: guideline on detection of toxicity to reproduction for medicinal products; availability. Federal Register 1994;59:48746-52.
118. Mino Y, Mizusawa H, Shita K. Effects of anticonvulsant drugs on fetal mouse palates cultured in vitro. Reprod Toxicol 1994;8:225-30.
119. Regan CM, Gorman AMC, Larsson OM, Maguire C, Martin ML, Shousboe A, Williams DC. In vitro screening for anticonvulsant induced teratogenesis in neural primary cultures and cell lines. Int J Dev Neurosci 1990;8:143-50.